1. Introduction {#sec1}
===============

*E. coli* is a common etiological factor of urinary tract infection, gastroenteritis, neonatal meningitis, and many nosocomial infections such as pneumonia, bloodstream infections, and surgical site infections \[[@B1]\]. The treatment of infections caused by*E. coli* is challenging, because of the increasing resistance of bacteria to antibiotics. The phenomenon of multidrug resistance has been reported worldwide and results in reduction of therapeutic possibilities \[[@B2]\].

The aim of this study was to evaluate the presence of*bla* genes responsible for carbapenemases production (*bla* ~KPC~, *bla* ~VIM~, *bla* ~IMP~, *bla* ~OXA-48~) and genes encoding other *β*-lactamases (*bla* ~SHV~, *bla* ~TEM~, *bla* ~CTX-M~). Additionally, we sought to determine the sequence type (ST) of a tested*E. coli* strain.

2. Materials and Methods {#sec2}
========================

The tested*E. coli* strain was isolated in February 2014 from the swab of an intestinal fistula obtained from a patient hospitalized in the intensive care unit at the University Hospital of Bialystok (Poland).

Biochemical identification (GN cards) and the preliminary susceptibility test (AST-N259 cards) were performed using the VITEK 2 automated system (bioMérieux, France). Additionally, the susceptibility to antibiotics of the tested strain was performed using*E*-tests (bioMérieux, France). The results of the susceptibility tests were interpreted according to EUCAST recommendations \[[@B3]\]. The screening detection of carbapenemases was performed according to EUCAST. Moreover, the biochemical Carba NP test was performed according to the Nordmann and Poirel protocol \[[@B4]\]. Further, molecular analysis was performed with the use of polymerase chain reactions (PCRs). Plasmid DNA was extracted with the use of Plasmid Mini (A&A Biotechnology, Gdynia, Poland) according to the manufacturer\'s instructions. PCR amplifications for*bla* genes responsible for carbapenemases production (*bla* ~KPC~, *bla* ~VIM~, *bla* ~IMP~, *bla* ~OXA-48~) and genes encoding other *β*-lactamases (*bla* ~SHV~, *bla* ~TEM~, *bla* ~CTX-M~) were performed using appropriate primers and conditions as described previously \[[@B5]--[@B8]\]. PCR amplicons were separated electrophoretically according to a previously described protocol \[[@B8]\]. Moreover, sequencing of*bla* amplicons was performed at Genomed (Warsaw, Poland). Multilocus sequence typing (MLST) was performed according to Institut Pasteur\'s MLST scheme (<http://www.pasteur.fr/recherche/genopole/PF8/mlst/primers_Ecoli.html>).

3. Results {#sec3}
==========

The combination disc assay showed that the difference in the size of the inhibition zone between meropenem and meropenem with boronic acid was higher than 7 mm. The biochemical Carba NP test was positive after 1 minute. The obtained results indicated carbapenem resistance mediated by KPC among the tested strains of*E. coli*.

The tested strain was analyzed for the presence of resistance mechanisms against *β*-lactam antibiotics using PCR amplifications for*bla* genes responsible for carbapenemases production (*bla* ~KPC~, *bla* ~VIM~, *bla* ~IMP~, *bla* ~OXA-48~) and genes encoding other *β*-lactamases (*bla* ~SHV~, *bla* ~TEM~, *bla* ~CTX-M~). The *bla* ~KPC~ and *bla* ~TEM~ genes were found in*E. coli*. The obtained sequence of the *bla* ~KPC~ gene showed identity with the sequence of the *bla* ~KPC-3~ gene (GeneBank accession no. AF395881.1). The obtained sequence of the *bla* ~TEM~ gene showed identity with the sequence of the *bla* ~TEM-34~ gene (GeneBank accession no. KC844056.1) responsible for production of broad-spectrum *β*-lactamase type TEM-34. Results of PCRs and minimum inhibitory concentration (MIC) values of tested antibiotics are presented in [Table 1](#tab1){ref-type="table"}.

The analysis of allelic profile (*dinB-5*,*icdA-37*,*pabB-4*,*polB-10*,*putP-78*,*trpA-8*,*trpB-2*,*uidA-30*) with use of the*E. coli* MLST sequence type database (<http://www.pasteur.fr/cgi-bin/genopole/PF8/mlstdbnet.pl?page=profile-query&file=Eco_profiles.xml>) showed that the tested*E. coli* strain belonged to the ST479 type.

4. Discussion {#sec4}
=============

A significant increase of*E. coli* isolates resistant to third-generation cephalosporins has been observed in Europe \[[@B9]\]. Studies have shown a high percentage (65%--100%) of extended-spectrum *β*-lactamase (ESBL) production among*E. coli* isolates resistant to third-generation cephalosporins \[[@B10]\]. One of the therapeutic options for treatment of infections due to ESBL-producing*E. coli* may be carbapenems. Resistance against carbapenems among*E. coli* rods is uncommon, which may be a result of AmpC *β*-lactamase production and loss of porins. Unfortunately, strains resistant to carbapenems due to the production of KPCs have recently been observed \[[@B11]\].

KPC producers have previously been reported in distinct geographic locations: European countries (Greece, Israel, Spain, Italy, Portugal, France, Poland, Germany, UK, and the Czech Republic), the United States, China, and South America \[[@B12]\]. KPC production is mainly prevalent among*Enterobacteriaceae* species. The significant majority of reports describe identification and the prevalence of *bla* ~KPC~ genes among nosocomial*K. pneumoniae* strains. Moreover, the occurrence of *bla* ~KPC~ genes among other*Enterobacteriaceae* species,*for example, E. coli*,*Enterobacter*, and*Citrobacter freundii* was observed \[[@B13]\]. The most commonly reported variant is KPC-2. Single reports describe the occurrence of KPC-3 among*E. coli* in Europe. In Spain, a multiresistant*E. coli* strain producing both KPC-3 and VIM-1 carbapenemases was described. In Italy, a KPC-3-producing*E. coli* isolate was found in abdominal drainage. Both cases were reported in 2014 \[[@B14]\]. Our study is first report of *bla* ~KPC-3~ genes in*E. coli* ST479, in Poland.
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MIC values of antimicrobial agents tested for *E. coli* 140 2594-2 and results of PCRs for *bla* genes.

  Antimicrobial agents            MIC \[*μ*g/mL\]                       
  ------------------------------- ------------------------------------- ---------
  Amikacin                        R 96                                  R ≥ 64
  Amoxicillin/clavulanic acid     N                                     R ≥ 32
  Cefepime                        I 4                                   I 2
  Piperacillin/tazobactam         R \> 256                              R ≥ 128
  Cefuroxime                      N                                     R ≥ 64
  Cefotaxime                      N                                     R 2
  Ceftazidime                     R \> 256                              R 32
  Colistin                        S 0.38                                S ≤ 0.5
  Ertapenem                       R 8                                   R 4
  Gentamicin                      R 16                                  I 4
  Tobramycin                      N                                     R ≥ 16
  Aztreonam                       R 192                                 N
  Imipenem                        I 3                                   I 8
  Meropenem                       S 0.75                                I 1
  Doripenem                       I 1.5                                 N
  Tigecycline                     S 1                                   S ≤ 0.5
  Ciprofloxacin                   N                                     R ≥ 4
  Trimethoprim/sulfamethoxazole   N                                     R ≥ 320
                                                                        
  Results of PCRs                                                       
  Genes encoding carbapenemases   Genes encoding other *β*-lactamases   
                                                                        
  *bla* ~KPC~-positive^\*^        *bla* ~TEM~-positive^\*\*^            
  *bla* ~VIM~-negative            *bla* ~SHV~-negative                  
  *bla* ~OXA-48~-negative         *bla* ~CTX-M~-negative                
  *bla* ~IMP~-negative                                                  

R: resistant; S: susceptible; I: intermediate; ^\*^genes encoding *β*-lactamase type KPC-3, ^\*\*^genes encoding *β*-lactamase type TEM-34; N: not tested.

[^1]: Academic Editor: Madhab K. Chattopadhyay
